Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
Therapeutic Advances in Medical Oncology|May 2, 2013
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospectsJohn Stagg, Bertrand AllardMethods in Molecular Biology (Clifton, N.J.)|September 2, 2016
Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical StudiesBertrand Allard, David Allard, John StaggExpert Opinion on Therapeutic Targets|May 7, 2014
Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancerBertrand Allard, Martin Turcotte, John StaggJournal of Biomedicine & Biotechnology|November 6, 2012
CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthBertrand Allard, Martin Turcotte, John StaggJournal for Immunotherapy of Cancer|February 27, 2020
On the mechanism of anti-CD39 immune checkpoint therapyDavid Allard, Bertrand Allard, John StaggSeminars in Immunology|October 13, 2019
Targeting the adenosine pathway for cancer immunotherapyAkil Hammami, David Allard, Bertrand Allard, et al.Nature Reviews. Clinical Oncology|June 10, 2020
The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Methods in Enzymology|November 16, 2019
Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assaysBertrand Allard, Isabelle Cousineau, Kathleen Spring, et al.Nature Reviews. Clinical Oncology|July 19, 2020
Publisher Correction: The adenosine pathway in immuno-oncologyBertrand Allard, David Allard, Laurence Buisseret, et al.Methods in Molecular Biology (Clifton, N.J.)|December 31, 2022
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor ModelsCelia Jacoberger-Foissac, Bertrand Allard, David Allard, et al.Pageof 4